Cat. #156374
Anti-ABeta (Abeta) [6C3]
Cat. #: 156374
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: Amyloid-? Peptide
Class: Monoclonal
Application: IHC ; WB
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: University of Illinois Chicago
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-ABeta (Abeta) [6C3]
- Alternate name: AÄÂ? or Abeta
- Research fields: Apoptosis and autophagy;Cell biology;Developmental biology
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: IHC ; WB
- Description: Defects in APP are associated with the pathology of various types of Alzheimer's disease. Specially, the defective amyloid-beta-APP 40-42 peptides, which MOAB-2 targets exclusively, are major constituents of extracellular plaques and contribute cytotoxic neuronal death.
- Immunogen: Human beta Amyloid. Recombinant oligomeric A?42. Epitope maps to residues 1-4 of human A?42 and A?40 (DAEF).
- Recommended controls: IgG2b
Target Details
- Target: Amyloid-? Peptide
- Tissue cell line specificity: IgG2b
- Target background: Defects in APP are associated with the pathology of various types of Alzheimer's disease. Specially, the defective amyloid-beta-APP 40-42 peptides, which MOAB-2 targets exclusively, are major constituents of extracellular plaques and contribute cytotoxic neuronal death.
Applications
- Application: IHC ; WB
Handling
- Format: Liquid
- Unit size: 100 ug
- Shipping conditions: Shipping at 4° C
References
- 295587871
- Fekete et al. 2019. Neuroscience. 405:35-46. PMID: 29522854.
- Scaringi et al. 2012. Anticancer Res. 32(10):4213-23. PMID: 23060541.
- Youmans et al. 2012. Mol Neurodegener. 7:8. PMID: 22423893.
- Youmans et al. 2012. Mol Neurodegener. 7:8. PMID: 22423893.
